Online Education

24HT00069 – The 340B Pharmacy Program and the HTC

January 10, 2024 

5:00 PM Eastern, January 9, 2026
The estimated time to complete this enduring material is 30 minutes.

The purpose of this module is to examine the 340B Pharmacy Program, its role in homecare of hemophilia, eligibility and enrollment, restrictions and requirements, and special considerations for operation of such a program. 

As designated in The Veterans Health Care Act of 1992 designated federally-recognized and federally-funded Hemophilia Diagnostic and Treatment Centers (HTCs) as covered entities eligible to participate in the 340B Drug Pricing Program. HTCs were henceforth able to utilize the 340B Program to stretch federal grant funding and develop capacity to provide robust, comprehensive services to all patients served. In 2015 federal grants divided among 140+ HTCs in the U.S. totaled only $4.9 million from Health Resources and Services Administration (HRSA) (to be used for services not covered by insurance) and an additional $5 million from the Centers for Disease Control and Prevention (CDC) (earmarked for surveillance and research).1 Thus, in this era of fiscal constraint brought on by budget cuts and the effects of federal sequestration, HTC participation in the 340B Pharmacy Program has provided a critical means of financial support for HTC services enabling provision of comprehensive care for all patients seen at HTCs with these programs. Approximately 100 of the 140 HTCs participate in the 340B Pharmacy Program.2 As a condition of participation, these centers must invest all revenues from the program back into patient services, care coordination, research and other programs that directly benefit patients. 

This module will provide a brief history of?the 340B Pharmacy Program established in 1992 under the Veterans Healthcare Act and the role of these programs in lowering costs of care and providing revenue for the HTC which must be reinvested into programs and services provided directly to HTC patients. For those HTCs in consideration of starting a 340B Pharmacy Program, this module also introduces the Office of Pharmacy Affairs requirements and regulations for such a program, including definitions of key terms and information about the application process, program maintenance, and potential program audits. Finally, this module will recommend the Hemophilia Alliance as a resource for HTCs with 340B Pharmacy Programs as well as those who are interested in learning more about the operation and management of such programs at HTCs.? 

This accredited continuing education activity is designed for nurses, pharmacists, pharmacy technicians, and other healthcare professionals in the U.S. Hemophilia Treatment Center (HTC) Network who wish to learn more about establishing and/or managing a 340B Pharmacy Program and the role of these programs in the U.S. HTC Network. 

At the conclusion of this activity, the participants should be better able to:

• Explain homecare provision and the role of the 340B Pharmacy Program 
• Summarize the importance of Section 340B of the Veterans Health Care Act 
• Describe 340B Pharmacy Program eligibility and enrollment 
• Identify restrictions and requirements to operate a 340B Pharmacy Program 
• Discuss special considerations of operating a 340B Pharmacy Program at a federally-recognized U.S. Hemophilia Treatment Center (HTC). 

In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In order for pharmacists/pharmacy technicians to claim credit for their participation in the activity, completion of the activity evaluation survey with inclusion of birth date (mm/dd) and NABP e-Profile ID # is required. UNMC will ensure that the data is provided to CPE Monitor.

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHARMACISTS (PharmDs/RPhs) AND PHARMACY TECHNICIANS  

The University of Nebraska Medical Center designates this activity for 0.5 ACPE contact hours. Pharmacists/Pharmacy Technicians should claim only the credit commensurate with the extent of their participation in the activity.?UAN # JA0000319-9999-24-004-H03-P / UAN # JA0000319-9999-24-004-H03-T 

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 463-238-1186 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser